Benoxaprofen is effective in the systemic treatment of psoriasis but is toxic. One of the goals of this application is to modify benoxaprofen for topical administration which should result in high concentrations at the lesion site, lower concentrations systemically, and improved safety. Thirteen compounds have been evaluated in the arachidonic acid mouse ear inflammation assay. Four of our compounds are more active than benoxaprofen in this model. 3890902 was more active (0.2

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44AR039427-02A2
Application #
3506286
Study Section
Special Emphasis Panel (SSS (B2))
Project Start
1991-02-01
Project End
1993-01-31
Budget Start
1991-02-01
Budget End
1992-01-31
Support Year
2
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Molecular Design International, Inc.
Department
Type
DUNS #
City
Memphis
State
TN
Country
United States
Zip Code
38111